Teprotumumab in thyroid eye disease

• Published in: Saudi journal of ophthalmology Vol. 38; no. 1; pp. 29 - 33
• Main Authors: Goldberg, Hila, Malik, Amina I
• Format: Journal Article
• Language: English
• Published: India Wolters Kluwer - Medknow 01.01.2024
• Subjects: Neuro-ophthalmology Update; proptosis; thyroid; targeted; graves; Autoimmune; teprotumumab; orbitopathy
• ISSN: 1319-4534; 2542-6680
• DOI: 10.4103/sjopt.sjopt_179_23

Thyroid eye disease (TED) is an inflammatory condition involving the periocular and orbital soft tissues, affecting most commonly patients with hyperthyroid disorders. Traditional treatments used for the active phase of the disease range from conservative lubrication for mild symptoms to systemic immunomodulating drugs for moderate-to-severe symptoms. Teprotumumab (Tepezza) is a monoclonal antibody with an inhibitory effect on insulin-like growth factor 1 and is the first Food and Drug Administration (FDA) approved targeted medical therapy for reducing the inflammatory signs and symptoms associated with TED. Two large multicenter, randomized, double-masked, placebo-controlled trials have confirmed the efficacy and safety of teprotumumab in patients with active, moderate-to-severe TED. Recent reports and publications have also demonstrated the efficacy of teprotumumab in a wider range of patients. In this review, we summarize the clinical features and pathophysiology of TED, disease course, and traditional management methods. We further detail the development of teprotumumab, the founding studies that brought it to its FDA approval, adverse events profile, and ongoing as well as future investigations.